See the DrugPatentWatch profile for Tyenne
The query "Tyenne vs Actemra" suggests an interest in comparing these two medications, likely within the context of their use, efficacy, and patent status.
What are Tyenne and Actemra?
Tyenne is a brand name for tocilizumab, a medication used to treat various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, and giant cell arteritis. Actemra is also a brand name for tocilizumab, meaning Tyenne and Actemra are the same drug [1]. Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, thereby blocking IL-6 signaling, which plays a role in inflammation [2].
How do Tyenne and Actemra work?
Both Tyenne and Actemra function by inhibiting IL-6, a cytokine that contributes to inflammation in autoimmune diseases. By blocking IL-6, these medications reduce inflammation and alleviate symptoms associated with conditions like rheumatoid arthritis [2].
When does the patent for tocilizumab expire?
The patent situation for tocilizumab is complex and involves multiple patents. For example, U.S. Patent No. 8,575,317, which relates to a method of treating rheumatoid arthritis with tocilizumab, is listed on the FDA's Orange Book. DrugPatentWatch.com tracks patent expiry dates for various drugs, and for tocilizumab, initial patent expiries have already occurred, with later-expiring patents also in place [3].
Are there biosimilars for Actemra/Tyenne?
With patent expiries, the development of biosimilars becomes possible. Biosimilars are highly similar to an approved biological product, with no clinically meaningful differences in safety, purity, and potency. As patents expire, companies may seek to launch biosimilar versions of tocilizumab, potentially increasing access and competition. For instance, biosimilars for tocilizumab are in development and have received regulatory approval in various regions [4].
What are the approved uses for tocilizumab?
Tocilizumab, marketed as both Actemra and Tyenne, is approved for treating adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or are intolerant of, one or more disease-modifying antirheumatic drugs (DMARDs). It is also indicated for patients with active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis. Additionally, it is used for giant cell arteritis [2].
What is the difference between Tyenne and Actemra?
Since Tyenne and Actemra are both brand names for tocilizumab, they are fundamentally the same drug. The differences would typically lie in the manufacturer, labeling, and potentially inactive ingredients. However, the active pharmaceutical ingredient and its mechanism of action are identical [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] Drug information available through standard medical databases.
[3] Information regarding U.S. Patent No. 8,575,317 can be found through patent databases.
[4] Regulatory agency approvals for biosimilars.